FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567375827> ?p ?o ?g. }

• W2567375827 abstract "The axiomatic tumor heterogeneity of human cancers and their resistance to current anticancer drugs has necessitated that we develop innovative treatment strategies. In this regard, combined drugs that impact two or more targets simultaneously are likely to offer superior chemosensitivity. Here, we describe the design and development of a compound with ROS-generating and microtubule-disrupting properties. Combretastatins (CA4) are small molecule cytotoxic agents of natural origin, known to disrupt microtubule dynamics by binding to the colchicine site and also inhibit angiogenesis. Despite the potent anticancer activity of CA4, the cis-configured double bond in its structure is prone for isomerization to the more stable trans form during storage and metabolism, resulting in loss of activity. In contrast, piperlongumine (PL), which has structural similarities with CA4, is known to selectively increase ROS levels and induce apoptosis in cancer cells. Here, we present the synthesis and biological evaluation of combretastatin-piperlongumine hybrid derivatives that inhibit tubulin polymerization, reactivate mutant p53 and induce oxidative stress in cancer cell lines. These CA4-PL hybrid derivatives were prepared by introducing the aryl group at the C7-carbon of piperlongumine in such a way that carbonyl group at C6 position will stabilize the cis-configuration between two aryl groups which is essential for the microtubule destabilization. The new compounds exhibited potent antiproliferative activities against a variety of cancer cell lines, particularly against cells with the DNA-contact p53 mutations, R175H (SKBR-3) and R273H (HT29). Cell cycle analysis revealed that CA4-PL analogs exhibited significant G2/M arrest and in vitro-tubulin polymerization assays confirmed the microtubule destabilizing actions. Immunocytochemistry revealed a loss of intact microtubule structure in cells treated with CA4-PL hybrid compounds, indicating the acquisition of combretastatin nucleus. Further, the compounds induced high levels of ROS selectively in cancer cells as determined by flow cytometry assays using DCF-DA. Most interestingly, the hybrid drugs showed the ability to reactivate the p53 mutations R273H and R175H- a progressive decline of mutant forms along with a gradual increase of wt p53 was evident from immunological assays using specific antibodies (Mabs 240 & 1620 respectively) and EMSAs. p53 reactivation was accompanied by the induction of the target genes, p21cip1 and Bax. We hypothesize that redox-perturbation induced by the hybrid drugs triggers the thiolation of specific redox-sensitive cysteines to cause p53 reactivation. Xenograft studies to test these observations in vivo are in progress. We believe such rationally designed compounds with dual actions hold much promise for drug development (supported by CPRIT grant RP130266 to KSS). Citation Format: Surendra R. Punganuru, Hanumantharao Madala, Kalkunte S. Srivenugopal. Hybrid anticancer drugs: Synthesis of a combretastatin-piperlongumine analog with mutant p53 reactivation and antimicrotubule properties. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3664. doi:10.1158/1538-7445.AM2015-3664" @default.
• W2567375827 created "2017-01-06" @default.
• W2567375827 creator A5002698143 @default.
• W2567375827 creator A5015226138 @default.
• W2567375827 creator A5033003394 @default.
• W2567375827 date "2015-08-01" @default.
• W2567375827 modified "2023-09-27" @default.
• W2567375827 title "Abstract 3664: Hybrid anticancer drugs: Synthesis of a combretastatin-piperlongumine analog with mutant p53 reactivation and antimicrotubule properties" @default.
• W2567375827 doi "https://doi.org/10.1158/1538-7445.am2015-3664" @default.
• W2567375827 hasPublicationYear "2015" @default.
• W2567375827 type Work @default.
• W2567375827 sameAs 2567375827 @default.
• W2567375827 citedByCount "0" @default.
• W2567375827 crossrefType "proceedings-article" @default.
• W2567375827 hasAuthorship W2567375827A5002698143 @default.
• W2567375827 hasAuthorship W2567375827A5015226138 @default.
• W2567375827 hasAuthorship W2567375827A5033003394 @default.
• W2567375827 hasConcept C105696609 @default.
• W2567375827 hasConcept C121608353 @default.
• W2567375827 hasConcept C185592680 @default.
• W2567375827 hasConcept C190283241 @default.
• W2567375827 hasConcept C20418707 @default.
• W2567375827 hasConcept C2778275628 @default.
• W2567375827 hasConcept C29537977 @default.
• W2567375827 hasConcept C502942594 @default.
• W2567375827 hasConcept C54355233 @default.
• W2567375827 hasConcept C55493867 @default.
• W2567375827 hasConcept C71240020 @default.
• W2567375827 hasConcept C84425145 @default.
• W2567375827 hasConcept C86803240 @default.
• W2567375827 hasConcept C95444343 @default.
• W2567375827 hasConcept C96232424 @default.
• W2567375827 hasConcept C98274493 @default.
• W2567375827 hasConceptScore W2567375827C105696609 @default.
• W2567375827 hasConceptScore W2567375827C121608353 @default.
• W2567375827 hasConceptScore W2567375827C185592680 @default.
• W2567375827 hasConceptScore W2567375827C190283241 @default.
• W2567375827 hasConceptScore W2567375827C20418707 @default.
• W2567375827 hasConceptScore W2567375827C2778275628 @default.
• W2567375827 hasConceptScore W2567375827C29537977 @default.
• W2567375827 hasConceptScore W2567375827C502942594 @default.
• W2567375827 hasConceptScore W2567375827C54355233 @default.
• W2567375827 hasConceptScore W2567375827C55493867 @default.
• W2567375827 hasConceptScore W2567375827C71240020 @default.
• W2567375827 hasConceptScore W2567375827C84425145 @default.
• W2567375827 hasConceptScore W2567375827C86803240 @default.
• W2567375827 hasConceptScore W2567375827C95444343 @default.
• W2567375827 hasConceptScore W2567375827C96232424 @default.
• W2567375827 hasConceptScore W2567375827C98274493 @default.
• W2567375827 hasLocation W25673758271 @default.
• W2567375827 hasOpenAccess W2567375827 @default.
• W2567375827 hasPrimaryLocation W25673758271 @default.
• W2567375827 hasRelatedWork W1976933010 @default.
• W2567375827 hasRelatedWork W1977345130 @default.
• W2567375827 hasRelatedWork W1984457940 @default.
• W2567375827 hasRelatedWork W2016206039 @default.
• W2567375827 hasRelatedWork W2062906704 @default.
• W2567375827 hasRelatedWork W2140137918 @default.
• W2567375827 hasRelatedWork W2146280808 @default.
• W2567375827 hasRelatedWork W2179574945 @default.
• W2567375827 hasRelatedWork W2523765732 @default.
• W2567375827 hasRelatedWork W2608785267 @default.
• W2567375827 hasRelatedWork W2883338656 @default.
• W2567375827 hasRelatedWork W2918438011 @default.
• W2567375827 hasRelatedWork W2999055642 @default.
• W2567375827 hasRelatedWork W3013059613 @default.
• W2567375827 hasRelatedWork W3018368155 @default.
• W2567375827 hasRelatedWork W3087165576 @default.
• W2567375827 hasRelatedWork W3162500615 @default.
• W2567375827 hasRelatedWork W3193948358 @default.
• W2567375827 hasRelatedWork W3196703635 @default.
• W2567375827 hasRelatedWork W53249366 @default.
• W2567375827 isParatext "false" @default.
• W2567375827 isRetracted "false" @default.
• W2567375827 magId "2567375827" @default.
• W2567375827 workType "article" @default.